Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Analysis of Differences of Serum Thromboxane B2 Level after Taking Acetosal in Acute Thrombotic Stroke with Diabetes Mellitus and Non-Diabetes Mellitus

Folia Medica Indonesiana · Vol. 54 No. 1 (2018) · hlm. 53–53

DOI
10.20473/fmi.v54i1.8053
ISSN
2355-8393, 2599-056X
Terbit
2018-04-05
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Endothelial dysfunction and vascular injuries are the early processes in thrombogenesis leading to thrombotic stroke. These processes trigger platelet activation characterized by synthesis of Thromboxane A2, potent agonist in platelet aggregation. Acetosal (ASA) 100 mg usually given to thrombotic stroke patients exerts its pharmacological effect by inhibition of TxA2 synthesis, thus could prevent thrombus formation. Diabetes mellitus (DM) as risk factor of thrombotic stroke exhibits an increase in TxA2 synthesis. It is not known whether ASA 100 mg could inhibit TxA2 adequately in diabetic patients. This study aimed to analyze the differences of serum TxA2 level, which was measured by serum TxB2 level as stabile metabolite of TxA2, after taking ASA 100 mg in diabetic and non-diabetic thrombotic stroke patients. This prospective observational study was held in Neurology Department of Dr. Soetomo Hospital, Surabaya. Total 27 patients, consisted of 15 patients with DM and 12 patients with non-DM were enrolled. Serum TxB2 was measured before and after 5-7 days 100 mg ASA 100 administration. Mean value of serum TxB2 level before and after taking ASA was 16.43 ± 16.08 ng/mL and 2.93 ± 1.83 ng/mL in diabetic and 27.36 ± 21.04 ng/mL and 5.36 ± 4.06 ng/mL in non-diabetic group. Mean reduction of serum TxB2 level in diabetic and non-diabetic group was 13.49 ± 15.9 ng/mL and 22.00 ± 21.65 ng/mL. There were significant differences in serum TxB2 level after taking ASA 100 mg in diabetic and non-diabetic group but the mean reduction of serum TxB2 level were not significantly different.

Kata kunci

Jaringan kolaborasi para penulis

32 penulis · 59 tautan kepenulisan bersama · 5 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Rumah Sakit Dokter Soetomo
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Yulistiani YulistianiUniversitas Airlangga2
Kuntaman KuntamanUniversitas Airlangga2
Binti MuzayyanahUniversitas Airlangga1
Nuraida WisudaniAfiliasi tidak diketahui1
Umul FadlilahUniversitas Airlangga1
Yudi Agung WibisonoAfiliasi tidak diketahui1
Mia MelindaUniversitas Airlangga1
Dhita Evi AryaniUniversitas Airlangga1
Nun ZairinaRumah Sakit Dokter Soetomo1
Landia SetiawanRumah Sakit Dokter Soetomo1
Ana Nurlaili HidayahUniversitas Airlangga1
Muqoddar ThayyibAfiliasi tidak diketahui1
Rino WahyudiAfiliasi tidak diketahui1
Ruhaya FitrinaAfiliasi tidak diketahui1
Khairil ArmalUniversitas Airlangga1
Adeltrudis AdelsaAfiliasi tidak diketahui1
Siti SjamsiahAfiliasi tidak diketahui1
Diny PuspitasariUniversitas Airlangga1
Taufiqur RahmanUniversitas Airlangga1
Usman HadiUniversitas Airlangga1
Nurul Ma'rifahUniversitas Airlangga1
Abdulloh MachinUniversitas Airlangga1
Maria Lettisia MeoUniversitas Airlangga1
Mirza JunandoAfiliasi tidak diketahui1
Achmad TarunaAfiliasi tidak diketahui1
I Dewa Gede UgrasenaUniversitas Airlangga1
Adinugraha AmarullahUniversitas Airlangga1
Ganesha T TrengginasUniversitas Airlangga1
Roni Agus SubagyoAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Analysis of Differences of Serum Thromboxane B2 Level after Taking Acetosal in Acute Thrombotic Stroke with Diabetes Mellitus and Non-Diabetes Mellitus</dc:title><dc:creator>Nur Hadiyanti</dc:creator><dc:creator>Didik Hasmono</dc:creator><dc:creator>Mohammad Saiful Islam</dc:creator><dc:subject>thromboxane B2</dc:subject><dc:subject>aspirin</dc:subject><dc:subject>acute ischemic stroke</dc:subject><dc:subject>diabetes mellitus</dc:subject><dc:subject>thromboxane A2</dc:subject><dc:subject>platelet aggregation</dc:subject><dc:subject>endothelial dysfunction</dc:subject><dc:subject>antiplatelet therapy</dc:subject><dc:subject>serum biomarkers</dc:subject><dc:description xml:lang="en">Endothelial dysfunction and vascular injuries are the early processes in thrombogenesis leading to thrombotic stroke. These processes trigger platelet activation characterized by synthesis of Thromboxane A2, potent agonist in platelet aggregation. Acetosal (ASA) 100 mg usually given to thrombotic stroke patients exerts its pharmacological effect by inhibition of TxA2 synthesis, thus could prevent thrombus formation. Diabetes mellitus (DM) as risk factor of thrombotic stroke exhibits an increase in TxA2 synthesis. It is not known whether ASA 100 mg could inhibit TxA2 adequately in diabetic patients. This study aimed to analyze the differences of serum TxA2 level, which was measured by serum TxB2 level as stabile metabolite of TxA2, after taking ASA 100 mg in diabetic and non-diabetic thrombotic stroke patients. This prospective observational study was held in Neurology Department of Dr. Soetomo Hospital, Surabaya. Total 27 patients, consisted of 15 patients with DM and 12 patients with non-DM were enrolled. Serum TxB2 was measured before and after 5-7 days 100 mg ASA 100 administration. Mean value of serum TxB2 level before and after taking ASA was 16.43 ± 16.08 ng/mL and 2.93 ± 1.83 ng/mL in diabetic and 27.36 ± 21.04 ng/mL and 5.36 ± 4.06 ng/mL in non-diabetic group. Mean reduction of serum TxB2 level in diabetic and non-diabetic group was 13.49 ± 15.9 ng/mL and 22.00 ± 21.65 ng/mL. There were significant differences in serum TxB2 level after taking ASA 100 mg in diabetic and non-diabetic group but the mean reduction of serum TxB2 level were not significantly different.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2018-04-05</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v54i1.8053</dc:identifier><dc:identifier>10.20473/fmi.v54i1.8053</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 54 No 1 (2018); 53-53</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/8053/4769</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>